Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zoldonrasib - REVOLUTION Medicines

Next Previous
Drug Profile

Zoldonrasib - REVOLUTION Medicines

Alternative Names: RMC-9805

Latest Information Update: 28 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REVOLUTION Medicines
  • Class Acetamides; Antineoplastics; Azabicyclo compounds; Aziridines; Cyclopentanes; Esters; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Indoles; Ketones; Methyl ethers; Morpholines; Piperazines; Pyridazines; Pyridines; Small molecules; Spiro compounds
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Solid tumours

Most Recent Events

  • 28 Oct 2026 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO, Tablet)
  • 14 Aug 2026 Phase-III clinical trials in Non-small cell lung cancer (First-line therapy, Combination therapy, Metastatic disease) in USA (PO) (NCT07777822)
  • 10 Aug 2026 BeOne Medicines and Revolution Medicines enters into licensing and clinical collaboration agreement for Zoldonrasib in Asia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top